Phase 3 study

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Eidos Therapeutics, a BridgeBio company
Registry number NCT06563895
Started 12 May 2025 Today 16 October 2026 Estimated completion 1 October 2031

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
St Vincent's Hospital Sydney Darlinghurst NSW Recruiting
Fiona Stanley Hospital Murdoch WA Recruiting
Westmead Hospital Westmead NSW Recruiting
Princess Alexandra Hospital Woolloongabba QLD Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years to 75 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 587

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Key Inclusion Criteria:

* Male or female ≥ 18 to ≤ 75 years of age inclusive.

* Participants must have an established genotype (hetero- or homozygosity) through a medically-indicated genetic test of a TTR gene variant that is known to be pathogenic or likely pathogenic (eg, V30M/p.V50M, V122I/p.V142I, T60A/p.T80A, or all other pathogenic TTR variants).

* Participant's age is within 10 years younger than or older than PADO.

Key Exclusion Criteria:

* Evidence of ATTR-CM or ATTR-PN.

* Current or past (within last 1 to 12 months, depending on specific agent) treatment with other TTR modifying therapies.

* Contraindication to or inability to undergo cardiac magnetic resonance testing.

* Major organ dysfunction, including: kidney disease, liver disease, heart disease (including cardiomyopathy), neuropathy

* Other diseases or conditions such has cancer within 5 years, untreated hyperthyroidism or hypothyroidism, type 1 diabetes, active hepatitis B or C, HIV.

* Major surgery within the past 3 months or planned during the next 12 months.

* Known hypersensitivity to acoramidis.

Dates on the record

Started 12 May 2025
Estimated completion 1 October 2031
Registry last updated 4 August 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 4 August 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.